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AbstractPneumocystis jirovecii causes severe interstitial pneumonia (PcP) in immunosuppressed patients. This multicentre study assessed the
distribution frequencies of epidemiologically relevant genetic markers of P. jirovecii in different geographic populations from Portugal, the
USA, Spain, Cuba and Mozambique, and the relationship between the molecular data and the geographical and clinical information, based
on a multifactorial approach. The high-throughput typing strategy for P. jirovecii characterization consisted of DNA pooling using
quantitative real-time PCR followed by multiplex-PCR/single base extension. The frequencies of relevant P. jirovecii single nucleotide
polymorphisms (mt85, SOD110, SOD215, DHFR312, DHPS165 and DHPS171) encoded at four loci were estimated in ten DNA pooled
samples representing a total of 182 individual samples. Putative multilocus genotypes of P. jirovecii were shown to be clustered due to
geographic differences but were also dependent on clinical characteristics of the populations studied. The haplotype DHFR312T/SOD110C/
SOD215T was associated with severe AIDS-related PcP and high P. jirovecii burdens. The frequencies of this genetic variant of P. jirovecii
were signiﬁcantly higher in patients with AIDS-related PcP from Portugal and the USA than in the colonized patients from Portugal, and
Spain, and children infected with P. jirovecii from Cuba or Mozambique, highlighting the importance of this haplotype, apparently
associated with the severity of the disease and speciﬁc clinical groups. Patients from the USA and Mozambique showed higher rates of
DHPS mutants, which may suggest the circulation of P. jirovecii organisms potentially related with trimethoprim-sulfamethoxazole
resistance in those geographical regions. This report assessed the worldwide distribution of P. jirovecii haplotypes and their
epidemiological impact in distinct geographic and clinical populations.
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CMI Esteves et al. Multicentre Pneumocystis pneumonia molecular epidemiology 566.e10IntroductionPneumocystis jirovecii pneumonia (PcP) is a major concern among
human immunodeﬁciency virus (HIV) -infected persons and
non-HIV-infected persons who are undergoing immunosup-
pressive treatments related to malignancies, connective tissue
diseases or organ transplantation [1–3]. Pulmonary coloniza-
tion with P. jirovecii in patients presenting with diverse levels of
immunodeﬁciency, primary respiratory disorders, or even in
the immunocompetent general population, is also an important
epidemiological issue, especially in terms of transmission [4–9].
Although a culture system to propagate P. jirovecii in vitro was
developed in 2014, it still needs to be validated, disseminated
and shown to be cost-effective for diagnostic purposes [10]. In
the absence of a well-established culture system to isolate and
maintain live organisms, previous efforts were made to un-
derstand the patterns of transmission so as to develop methods
of detection, intervention, characterization and management
for P. jirovecii [11–19]. Recently, the de novo assembly of the
P. jirovecii genome was published, opening the way to solve
some critical issues, such as the identiﬁcation of nutritional
supplements for the development of reliable and cost-effective
culture in in vitro systems, and detection of new targets for
development of anti-PcP drugs and vaccines [20]. The multiplex
ampliﬁcation of genomic P. jirovecii DNA associated with single
base extension (SBE) and DNA pooling was reported to be a
reliable alternative high-throughput DNA sequencing tech-
nique, allowing the calculation of the single nucleotide poly-
morphism (SNP) allele frequencies in a large number of samples
[21,22]. DNA pooling is a reliable and time-saving method for
genotyping screenings, in which equal amounts of DNA from a
large number of individual samples are pooled and the SNP
allele frequencies are estimated [21].
In the last two decades, several P. jirovecii DNA regions
were studied and speciﬁc SNPs associated with parameters of
P. jirovecii infection were identiﬁed [2,3,14–18,23–25]. The
mitochondrial large subunit ribosomal RNA (mtLSUrRNA) is a
conserved multicopy gene with a central role in basic meta-
bolic mechanisms during translation, providing peptidyl
transferase activity to the mitochondrial ribosome
[11,14,18,19,22]. Genetic variations at base 85 of the
mtLSUrRNA gene were recognized to be potentially associated
with high P. jirovecii burden levels and unfavourable follow up
of infection [21,22]. The dihydropteroate synthase (DHPS) and
dihydrofolate reductase (DHFR) genes encode for two
P. jirovecii central enzymes in the folate synthesis. Signiﬁcant
associations between the SNP at bases 165 and 171 of DHPS
and the use of sulfa drugs for PcP prophylaxis [2,15,17,25] or
failure of both trimethoprim-sulfamethoxazole treatment [26]© 2016 European Society of Clinical Microbiology and Infand trimethoprim-sulfamethoxazole or dapsone prophylaxis
[3], were reported. Additionally, P. jirovecii may evolve under
pressure from DHFR inhibitors, such as trimethoprim or py-
rimethamine, and mutations in this gene may contribute to
drug resistance [23,24,27]. The SNP at position 312 was
associated previously with PcP infection burden [18]. Super-
oxide dismutase (SOD) is involved in the protective mecha-
nisms of P. jirovecii against reactive oxygen radicals produced
by alveolar macrophages or neutrophils [22,28]. The major
genetic variations of the SOD locus (bases 110 and 215) are
reported to be at linkage disequilibrium and associated with
severity of PcP episodes [18,21,22,28].
This report is the ﬁrst multicentre P. jirovecii molecular study
in different geographic populations from four different conti-
nents. The aims were: to evaluate the distribution frequencies
of speciﬁc genetic markers in four P. jirovecii loci, in populations
from ﬁve different geographic origins (Portugal, the USA, Spain,
Cuba and Mozambique), including important genomic regions
involved in basic metabolic mechanisms, such as the
mtLSUrRNA, SOD, DHFR and DHPS and to epidemiologically
assess the relationship between the molecular data and the
geographical and clinical information.Materials and MethodsSubjects and data
A cohort of 182 respiratory specimens tested previously and
found to be positive for P. jirovecii by real-time quantitative PCR
(qPCR) were included in the study. Specimens included bron-
choalveolar lavage ﬂuids and induced sputa (adult patients) or
nasopharyngeal swabs (children) collected during routine diag-
nostic procedures/clinical care in ﬁve different geographical
locations (multicentre study). In each healthcare/diagnostic
centre, data were collected using standardized data collection
forms. The present study had the approval of the Institutional
Review Boards/Ethical Committees from the involved in-
stitutions. The clinical and demographic data are summarized in
Table 1.
Pneumocystis jirovecii burden was quantiﬁed in the 70 AIDS-
related PcP episodes from Portugal by scoring the number of
cysts observed by applying the semi-quantitative method of
indirect immunoﬂuorescence staining with monoclonal anti-
bodies (MonoFluoTM kit P. jirovecii; Bio-Rad, Marnes-la-
Coquette, France) and designated as low/moderate (one to
three cysts in one ﬁeld at × 1000) in 38 cases, and as heavy
(four or more cysts in one ﬁeld at × 1000) in 32 cases. Follow
up was possible in 53 of the 90 Portuguese patients with PcP. A
follow up was considered positive when the patient showed aectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 22, 566.e9–566.e19
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Abbreviations: HIV (+), HIV-positive patients; HIV (−), HIV-negative patients; BAL, bronchoalveolar lavage; IS, induced sputum; IF/mAb, indirect immunoﬂuorescence staining with
monoclonal antibodies; nPCR, nested PCR directed to P. jirovecii mtLSU rRNA gene; NP, nasopharyngeal; COPD, chronic obstructive pulmonary disease.
aSix patients with neoplasia, ﬁve organ transplantation recipients and nine patients with no available data to establish the immune status.
bAdult patients hospitalized with microscopically conﬁrmed PcP without demographic information.
cPatients with no available data to establish immune status.
dYoung children infected with P. jirovecii, presenting respiratory symptoms. Due to the low sensitivity of the NP swab, detection of P. jirovecii was possible only by nPCR.
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at least 4 weeks after the diagnosis of PcP. Negative follow up
was established either when there was a negative response to
anti-P. jirovecii therapy (failure to improve clinically after
administration of the drug for more than 10 days) or when the
patient died during a PcP episode [18,21].
DNA pooling
After collection, the samples from the ﬁve cohorts were pro-
cessed and immediately stored at −20°C for further analysis. All
specimens were subjected to DNA extraction using the Qiamp
kit (Qiagen, Hilden, Germany). Molecular detection of P. jirovecii
was performed by nested-PCR (nPCR) directed to the P. jirovecii
large subunit mitochondrial rRNA (mtLSUrRNA) gene [7,12,29].
All respiratory specimens were conﬁrmed to be positive for
P. jirovecii by qPCR targeting the kexin-like serine protease
(KEX1) gene of P. jirovecii [13,21].
Pneumocystis jirovecii DNA pools were planned based on
geographical origin and clinical data. DNA quantiﬁcation of each
individual respiratory specimen was achieved using the qPCR
targeting the KEX1 gene of P. jirovecii. The assay was performed in
the 7300 Real-Time PCR System (Applied Biosystems, Foster
City, CA, USA), using the TaqMan® Gene Expression with minor© 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elseviergroove binder probes FAM™ dye-labelled (Applied Biosystems):
2 min at 50°C, 10 min at 95°C and 50 ampliﬁcation cycles of 15 s
at 95°C and 1 min at 60°C using a 9-μL DNA sample, 1× Taq-
Man® Gene Expression Master Mix (Applied Biosystems), 1×
TaqMan® Gene Expression Assay (forward primer 50-
CAACCCTGTTCCAATGCCTAA-30, reverse primer 50-CAA-
CACCGATTCCACAAACAGT-30 and minor groove binder
probe 50-TGCTGGTGAAGTAGCTGCCGTTCGA-3’; Applied
Biosystems), in a 20-μL reaction volume. The baseline was taken
from cycles three to 15 and the threshold was set at 0.02. The
amount of P. jirovecii DNA present in each individual sample was
calculated applying the standard P. jirovecii DNA pattern curve
CT = −3.4323 log10 [KEX1] + 20.3610, in which CT is the
quantiﬁcation cycles and [KEX1] is the concentration of the
KEX1 fragments (ng/mL). This standard curve represents the
relationship between P. jirovecii KEX1 gene fragment concentra-
tion and qPCR CT values, previously estimated using serial di-
lutions of KEX1 PCR product suspensions quantiﬁed by the
PicoGreen dsDNA quantiﬁcation reagent method [13,21].
The respiratory specimens were diluted (1: 20) and the
respective CT values were estimated and converted into P. jirovecii
DNA concentration (ng/mL) using the standard curve. The con-
centration of KEX1 gene copies (copies/μL) was derived from theLtd. All rights reserved, CMI, 22, 566.e9–566.e19
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fragment molecular weight (229 091.67 g/mol). As the KEX1 is a
nuclear single-copy gene, the number of copies per microlitre
corresponds to the P. jirovecii genome concentration. The average
genome concentrations (P. jirovecii genomes/μL) of the pooled
P. jirovecii samples were PT1 2.89 × 106, PT2 8.74 × 106, PT3
2.00 × 106, PT4 1.69 × 106, PT5 7.59 × 106, PT6 2.51 × 106, USA
1.42 × 107, MOZ 1.74 × 107, SPA 1.85 × 107 and CUB 1.13 × 109.
Equivalent amounts of DNA (1 × 10−5 ng) from each of the
individual samples were proportionally combined in the cor-
responding pool, according to geographical origin and/or clinical
data, as follows.
Portugal Pool 1 (PT1). Thirty-eight respiratory specimens from
HIV-positive adult patients with AIDS-related PcP (positive
microscopy, positive nPCR), presenting low/moderate parasite
burden.
Portugal Pool 2 (PT2). Thirty-two respiratory specimens from
HIV-positive adult patients with AIDS-related PcP (positive
microscopy, positive nPCR), presenting high parasite burden.
Portugal Pool 3 (PT3). Eighteen respiratory specimens from
HIV-positive adult patients PcP-negative (negative microscopy,
positive nPCR) with other pulmonary diseases, colonized by
P. jirovecii (subclinical infection).
Portugal Pool 4 (PT4). Twenty respiratory specimens from
HIV-negative adult patients with PcP (positive microscopy,
positive nPCR).
Portugal Pool 5 (PT5). Thirty-ﬁve respiratory specimens from
HIV-positive adult patients with PcP, presenting clinical
improvement (positive follow up).
Portugal Pool 6 (PT6). Eighteen respiratory specimens from
HIV-positive adult patients with PcP who failed to improve
clinically or died during the PcP episode (negative follow up).
USA Pool. Thirty respiratory specimens from HIV-positive
patients with severe AIDS-related PcP (positive microscopy,
positive nPCR).
Mozambique Pool. Twenty-two respiratory specimens from
infants infected with P. jirovecii, presenting respiratory symp-
toms (negative microscopy, positive nPCR).
Spain Pool. Twelve respiratory specimens from HIV-positive
and HIV-negative adult patients colonized by P. jirovecii, pre-
senting with other respiratory diseases than PcP (negative mi-
croscopy, positive nPCR).
Cuba Pool. Ten respiratory specimens from HIV-negative
young children infected with P. jirovecii, presenting respiratory
symptoms (negative microscopy, positive nPCR).
Genotyping
The P. jirovecii DNA pools were studied using the multiplex-
PCR (MPCR)/SBE technique (in triplicate), as described previ-
ously [21,22]. Four P. jirovecii hot spots (mtLSUrRNA, SOD, DHFR© 2016 European Society of Clinical Microbiology and Infand DHPS) were simultaneously ampliﬁed using an MPCR (T1
Thermocycler; Biometra, Göttingen, Germany), as follows:
10 min at 95°C, followed by 45 ampliﬁcation cycles of 1 min at
95°C, 1 min 60°C and 1 min at 72°C, and a ﬁnal extension of
10 min at 72°C, using 4 μL DNA sample, 2.5 U AmpliTaq Gold
DNA polymerase (Applied Biosystems), 1.5 × reaction buffer
(75 mM KCl, 15 mM Tris–HCl (pH 8.3); Applied Biosystems),
0.5 mM deoxynucleoside triphosphates (dNTPs) (Applied Bio-
systems), 4 mM MgCl2 (Applied Biosystems), 0.01 μg/μL bovine
serum albumin (Sigma–Aldrich, Cleveland, OH, USA), 0.75 μL
dimethylsulphoxide (DMSO) (Sigma–Aldrich), 0.5 μM of
mtLSUrRNA primers (pAZ102-X and pAZ102-E), 1.4 μM of
SOD primers (MnSODFw and MnSODRw2), 0.7 μM of DHPS
primers (DHPSFw1 and DHPSRv1), and 1.4 μM of DHFR
primers (FR 208 and FR 1018), in a 50-μL reaction volume.
Except for DHPSFw1 (50-CGATGGGGGTGTTCATTCA-
TATG-30) and DHPSRv1 (50-GCCTTAATTGCTTGTTCTG-
CAACC-30), all primers were described previously
[11,16,19,21–23,29].
The MPCR products (10 μL) were incubated with shrimp
alkaline phosphatase (2 U) (USB Corporation, Cleveland, OH,
USA) and exonuclease I (4 U) (USB Corporation) for 1 h at 37°
C (20 μL reaction volume). After inactivation of the enzymes
(15 min at 96°C), 5 μL of treated MPCR products were used in
the SBE reaction (15 μL reaction volume): 1 min at 90°C, fol-
lowed by 45 SBE cycles of 10 sec at 90°C and 20 sec 45°C,
using 4 μL SNPStart Master Mix (GenomeLab SNPStart primer
extension kit; Beckman Coulter, Brea, CA, USA) and SBE-TAG
probes (2.7 μM DHFR312, 0.3 μM mt85, 0.6 μM DHPS165, 1.2
μM SOD215, 2.1 μM SOD110, 0.9 μM DHPS171) (Euroﬁns
Genomics, Ebersberg, Germany). Except for DHPS165 (50-
GGATAAATATCTAACACCGTGCGTGTTGACTATTATTG
ATATTGGTGGGCAGTCT-30) and DHPS171 (50-CCAAAGT
TCTCAATGCTGCTTGCTGTTCTTGAATGGGGGGTCGT
TGACGACGACATCTATAGAAACAACATSTGAACCAG-30,
in which S corresponds to Deoxyinosine), all SBE-TAG probes
were described previously [22]. The SBE products were treated
with shrimp alkaline phosphatase (0.5 U) for 1 h at 37°C, fol-
lowed by enzyme inactivation (15 min at 96°C). The MPCR/SBE
products were analysed in a CEQ 8000-XL (Beckman Coulter)
[21].
The MPCR/SBE-DNA pooled products were characterized
through length discrimination (nucleotides, nt) provided by the
SBE-TAG probes (35 nt DHFR312, 47 nt mt85, 55 nt
DHPS165, 64 nt SOD215, 75 nt SOD110, 82 nt DHPS171) and
identiﬁed by the ﬂuorescence-labelled ddNTPs (D1-red
adenine, D2-black cytosine, D3-green guanine and D4-blue
thymine). A reference positive control (GenomeLab SNPStart
primer extension kit; Beckman Coulter) with four control



































































































































































































































































































566.e13 Clinical Microbiology and Infection, Volume 22 Number 6, June 2016 CMID3-green guanine and 50 nt D4-blue thymine) was run in each
SBE assay. The average normalized relative frequencies of the
SNP alleles in each DNA pool sample were calculated by
dividing the maximum height values of ﬂuorescence peaks
observed in the SBE products by the reference ﬂuorescence
values of the positive control.
Data analysis
To overcome the failure of normality necessary for the appli-
cation of Student’s t-test, the Kruskal–Wallis non-parametric
test was used to analyse the differences in the SNP frequency
distribution variation across the pools. The signiﬁcance level
considered in all the statistical tests was 0.05 [21,22].
The most representative multilocus genotypes (MLG) (SNP
frequencies >32% for mt85 and 50% for the remaining SNP) of
each pool were analysed and a dendrogram was computed









































































































































































































































































































































































































































































































































































































































































According to the Kruskal–Wallis test, the median Cq values
and genomes concentration were statistically different between
several pools: PT1 versus PT2 (p 0.011); PT2 versus PT3 (p
<0.001); PT2 versus PT4 (p <0.001); PT3 versus PT5 (p 0.002);
PT3 versus MOZ (p 0.004); PT4 versus PT5 (p <0.001); PT4
versus USA (p 0.003); PT4 versus MOZ (p <0.001); PT4 versus
SPA (p 0.035); PT4 versus CUB (p 0.011).
Genotyping
In all, 182 pulmonary specimens divided into ten DNA pools
were analysed for the epidemiological distribution of P. jirovecii
genotypes in distinct geographic regions and among patients
presenting with different clinical conditions. The six SNP,
located in the four genetic loci studied, were successfully
characterized by the Multiplex-SBE/DNA pooling method in all
DNA pools. Fluorescence peaks with 35 nt (DHFR312), 47 nt
(mt85), 55 nt (DHPS165), 64 nt (SOD215), 75 nt (SOD110)
and 82 nt (DHPS171) were detected in the SBE reactions and
the average normalized relative frequencies of each SNP allele
were estimated (Table 2, Fig. 1). Data analysis demonstrated
several signiﬁcant statistical differences in the frequency distri-
bution of SNP among pools from different geographic origins
and with distinct parameters of infection (Table 3).
The relationships between the most relevant putative MLG
identiﬁed in the pools studied were analysed applying the
neighbour joining method. The most representative putative
MLG (SNP frequencies >32% for mt85 and 50% for the© 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 22, 566.e9–566.e19
FIG. 1. Graphic representation of Pneumocystis jir-
ovecii single nucleotide polymorphism alleles relative
frequencies among the different pools studied. Radar
charts were drawn with axes for each single nucle-
otide polymorphism (represented from the centre to
the periphery) and a scale in the range of 0-100%
(10% intervals).
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TABLE 3. Multiple comparisons of the Pneumocystis jirovecii
single nucleotide polymorphisms frequency distribution
variation across the pools studied
SNPs Multiple comparison analysis (p values)a
mt85A PT1 vs. PT2 (0.0042); PT2 vs. SPA (0.0011);
SPA vs. MOZ (0.0053)
mt85C PT1 vs. PT2 (0.0442); PT1 vs. PT6 (0.0061); PT3 vs. PT6 (0.032);
PT2 vs. SPA (0.0451); PT6 vs. SPA (0.0131)
mt85T PT3 vs. PT5 (0.0462); USA vs. CUB (0.0353)
DHPS165A/G PT1 vs. USA (0.0191); PT2 vs. USA (0.0131);
PT3 vs. USA (0.0021); USA vs. SPA (0.0083)
DHPS171C/T NSb
DHFR312T/C PT2 vs. PT3 (0.012); PT3 vs. USA (0.0151)
SOD110T/C USA vs. CUB (0.0093)
SOD215C/T PT2 vs. CUB (0.0321); USA vs. CUB (0.0093)
Abbreviations: PcP, Pneumocystis jirovecii pneumonia; PT1, AIDS-related PcP
Portuguese patients with low/moderate parasite burden; PT2, AIDS-related PcP
Portuguese patients with high parasite burden; PT3, HIV-positive PcP-negative
Portuguese patients with other pulmonary diseases, colonized by P. jirovecii; PT4,
HIV-negative Portuguese patients with PcP; PT5, Portuguese patients with PcP
presenting positive follow-up; PT6, Portuguese patients with PcP presenting
negative-up; USA, AIDS-related PcP patients from USA; MOZ, Mozambican infants
infected with P. jirovecii, presenting respiratory symptoms; SPA,
immunocompromised Spanish patients colonized by P. jirovecii, presenting other
respiratory diseases than PcP; CUB, HIV-negative young children infected with
P. jirovecii, presenting respiratory symptoms.
aFor the multiple comparisons of the pools, the p values presented are the adjusted
p values (Bonferroni correction) that took into consideration the number of
comparisons, i.e. the adjusted p value = p value k(k – 1)/2, with k = 10 the number
of pools to be compared is 45. The multiple comparisons were performed
considering three groups of pools: (1) All ten pools; (2) only the six Portuguese
pools; (3) only the four foreign pools.
bNS, not signiﬁcant, p >0.05.
566.e15 Clinical Microbiology and Infection, Volume 22 Number 6, June 2016 CMIremaining SNP) were considered in the construction of a
speciﬁc dendrogram (Fig. 2) in which three major clusters were
identiﬁed: cluster A with MLG from Spain (SPA-A, SPA-B),
Cuba and Portugal (PT1-A, PT3); cluster B with MLG from
Portugal (PT1-B, PT2, PT4, PT5, PT6); cluster C with MLG
from Mozambique and USA (USA-A,B,C,D).DiscussionTo our knowledge, this is the ﬁrst report on P. jirovecii
mtLSUrRNA and DHPS gene variability in Mozambique, DHFR
gene variability in Mozambique, Cuba and Spain, and SOD gene
variability in the USA, Mozambique and Spain. The results
strengthen the hypothesis that both geographic distances and
clinical parameters have direct impact in the distribution of the
genetic subtypes of P. jirovecii as demonstrated in Figs. 1 and 2.
In the Portuguese pools, data on genome concentrations
are consistent with P. jirovecii burden, with the pool PT2
(AIDS-related PcP patients with high parasite burden) pre-
senting the highest P. jirovecii genome concentration. The high
concentration of P. jirovecii genomes detected in the pools
from Cuba and Mozambique suggests that both populations
were infected with high burdens of P. jirovecii, which was not
initially detected, probably due to the low sensitivity and
difﬁculty in reading of the microscopic diagnostic method
using Giemsa staining [30].© 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by ElseviermtLSUrRNA
In Portugal, mt85C has been reported as the most frequent
allele of the SNP mt85 among HIV-positive patients with PcP
(mt85C 58.0%–63.0%, mt85A 26.0%–43.0% and mt85T
18.0%–22.0%, time period 1997–2007) [12,18,19,22]. In the
present study, except for the pool PT1, the Portuguese pools
demonstrated mt85A as the most frequent allele. The allele
mt85C was statistically associated with the pool PT1 (Tables 2
and 3). This ﬁnding is similar to previous reports, in which
low/moderate P. jirovecii burden was more frequently observed
among respiratory specimens with mt85C, whereas high bur-
dens were more frequently detected in respiratory specimens
with mt85A or mt85T [18,19,21]. The differences observed
between the present and previous data may be the result of the
different time periods of the studies (2004–2013 and
1997–2007, respectively).
In the USA, the distribution pattern of mt85 (mt85C 31.5%,
mt85A 61.1% and mt85T 7.4%) was similar to previous studies
(mt85C 42.9%–43.9%, mt85A 36.7%–50.0% and mt85T
7.1%–9.3%, in a population of PcP patients, time period
1986–1999) [14,31], particularly in San Francisco, with mt85C
25.0%, mt85A 50.0% and mt85T 7.0% (mixed genotypes 18.0%)
(in HIV-positive patients) [14]. In the AIDS-related PcP patients
from San Francisco, the distribution pattern of mt85 is relatively
stable in different time periods (2004–2012 and 1995–1998).
Pools from Mozambique and Cuba showed similar distribu-
tion patterns of mt85 (mt85C 16.5%, mt85A 72.5%, mt85T
10.9% and mt85C 11.4%, mt85A 63.0%, mt85T 25.7%, respec-
tively). Two recent Cuban studies, in a population of children
colonized by P. jirovecii (both time periods 2010–2013)
demonstrated analogous distribution patterns of mt85, with
mt85C 18.0%–31.0%, mt85A 56.0%–68.0% and mt85T
25%–37% [5,6]. The similarity between the results from
Mozambique and Cuba may be due to the fact that both pools
were constituted by populations of young children infected with
P. jirovecii and presenting analogous clinical parameters.
Since 2003, several studies in Spain demonstrated mtLSUrRNA
variation patterns (mt85C 40.0%–55.1%, mt85A 10.1%–18.2%
and mt85T 25.0%–36.7% in the general population, in HIV-
positive patients with PcP, and in HIV-negative patients with
other concomitant pulmonary disorders, between 1995 and
2008) [4,8,9,12]. Except for the general population study (mt85C
and mt85A both most prevalent), mt85C was the most prevalent
allele in all the other populations, followed by mt85T and mt85A.
The present data showed a change in the allelic distribution of
mt85 in Seville, Spain, particularly an increase of the mt85A.
These differences appear to be more related to the periods in
which the populations were studied (2006–2013 in the present
study, and 1995–2008 in the earlier studies) than with the
characteristics of the population, since the studies of Montes-Ltd. All rights reserved, CMI, 22, 566.e9–566.e19
FIG. 2. Dendrogram showing the relationships between the Pneumocystis jirovecii putative multilocus genotypes (MLG) from different geographic
origins, constructed on the base of the four polymorphic markers (mtLSUrRNA, DHPS, DHFR and SOD) and demonstrating that genetic differences
between clusters associated mainly with geographic differences, but also with the clinical set up in the different pools. Dendrogram was computed using
the software CLUSTAL W2 multiple sequence alignment (version 2.0.12). The most representative putative MLG of P. jirovecii in the pools (single
nucleotide polymorphism frequencies higher than 32% for mt85 and 50% for the remaining single nucleotide polymorphism) studied were as follows:
PT1-A: mt85C/DHPS165A/DHPS171C/DHFR312T/SOD110T/SOD215C
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ulations similar to those in the present study.
DHPS
In Portugal, a decline of DHPS gene mutation frequencies has
been documented since the beginning of the 2000s. Frequencies
of 24.7% DHPS165G and 22.5% DHPS171T were detected in a
population of HIV-positive and HIV-negative patients with pul-
monary disorders, between 1994 and 2001, in which DHPS
mutations were more frequent in the time period 1994–1997
(33%) than in 1998–2001 (9%) (p 0.022) [32]. More recently,
the proportion of mutant DHPS alleles in a population of HIV-
positive patients was 7.0% DHPS165G and 9.0% DHPS171T,
between 2001 and 2007 [19]. The decline of DHPS mutant al-
leles among the HIV-positive patients (pools PT1, PT2 and PT3,
time period 2004–2012) may be attributed to the lack of
exposure to trimethoprim-sulfamethoxazole in this population,
after the decreased use of sulfa prophylaxis due to widespread
use of potent combination antiretroviral therapy in Europe, in
the late 1990s [2,12,32]. However, in the HIV-negative patients
with PcP (pool PT4), the frequencies of DHPS mutants,© 2016 European Society of Clinical Microbiology and Infespecially DHPS165G, appeared to be slightly higher than the
ones reported in the HIV-positive patients. The reason for this
observation is unclear. One possible explanation is that these
groups are clinically distinct, reﬂecting different trimethoprim-
sulfamethoxazole exposure, which may have an impact on the
genetic variability of the DHPS locus in P. jirovecii [33,34].
In the USA, since 1998, several studies have reported DHPS
mutations per PcP cases ranging from 26% to 81%, describing
high overall frequencies of DHPS165G and DHPS171T in
different time periods (7.4%–77.3% and 22.2%–59.4%, respec-
tively, from 1976 to 2001 [3,14,15,17,31,35]), especially in San
Francisco (65.0% DHPS165G, 64.0% DHPS171T) [18]. In this city,
several reports consistently described overall high frequencies of
mutations in the DHPS gene (87.0%, 1995–1998 [14]; 81.5%,
1996–1999 [17]; 81.4%, 1997–2002 [15]). The high frequencies
of DHPS mutants in the US pool (Fig. 1) is of concern and may
reﬂect trimethoprim-sulfamethoxazole exposure of the AIDS-
related PcP population and increased of sulfa-induced mutants,
especially after the mid-1990s [3,14,23].
In the early 2000s, several studies described low frequencies
of DHPS mutations in African countries neighbouringectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 22, 566.e9–566.e19
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wean AIDS-related PcP patients, 1992–1993 [36]; DHPS165G
1.9% and 10.0%, DHPS171T 1.9% and 6.7% in South African
adult patients with PcP and in HIV-infected children, respec-
tively, 2000–2003 [37,38]). The low frequencies were attrib-
uted to the lack of exposure to trimethoprim-sulfamethoxazole
in the populations studied [37,39]. However, in South Africa
rates of DHPS165G 44.0% and DHPS171T 41.1% were reported
in HIV-infected adult patients suspected of having PcP (time
period 2006–2007) [38]. The results of the present study
showed similar high prevalence of DHPS mutants in Mozambi-
can infants with P. jirovecii infection in an overlapping time
period (2006–2007). In this region of southeastern Africa, the
differences in the percentage of P. jirovecii DHPS mutations may
be due to different time periods of study, reﬂecting the
increased widespread empirical use of trimethoprim-
sulfamethoxazole, the mainstay of PcP treatment and prophy-
laxis regimens in sub-Saharan Africa, in the late 2000s [38]. But
it can also be attributed to an increased awareness by clinicians
leading to higher rates of diagnosis and subsequently higher
detection rates of DHPS mutations.
In contrast to the USA and Mozambique, pools from Spain
and Cuba showed low frequencies of DHPS mutants (Fig. 1). In
Spain, the reported frequencies of DHPS mutants vary from 0%
in the general population [8] to 15% for both DHPS165G and
DHPS171T in HIV-positive and HIV-negative patients with pul-
monary disorders [12]. One study involving HIV-negative pa-
tients with chronic pulmonary disease colonized by P. jirovecii
showed frequencies of DHPS165G 21.4% and DHPS171T 14.3%
(time period 2001–2002) [7]. Another study in AIDS-related
PcP patients, detected frequencies of DHPS165G 16.1% and
DHPS171T 12.8% (time period 2001–2003) [4]. These differ-
ences may be due to the lack of exposure to trimethoprim-
sulfamethoxazole in the general population, when compared
with AIDS-related PcP patients, who are more likely to be
treated with that drug combination in prophylactic or thera-
peutic doses.
In Cuba, a recent study showed a frequency of 12.0% for
both DHPS165G and DHPS171T in young children with
whooping cough, colonized by P. jirovecii (between 2010 and
2013) [6]. This distribution pattern is consistent with the pre-
sent results in Cuban HIV-negative young children infected with
P. jirovecii, in a coincident time period (2013). The detection of
low frequencies of DHPS mutations in Cuban children is most
probably due to the lack of exposure of this speciﬁc population
to trimethoprim-sulfamethoxazole.
DHFR
In Portugal, DHFR312T was the most prevalent DHFR allele, as
has been found in previous studies [18,19,21]. The frequency of© 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by ElsevierDHFR312C in AIDS-related PcP patients (PT1 and PT2) was
similar to those previously found in Portuguese HIV-positive
patients (21%–25%, 1997–2007 [19]; and 10%, 2001–2008
[21]). DHFR312C frequency was considerably higher in HIV-
positive patients colonized by P. jirovecii (PT3) and HIV-
negative PcP patients (PT4) that normally present lower
P. jirovecii burdens than AIDS-related PcP patients (Fig. 1,
Tables 2 and 3). The difference observed may be due to the
recently reported association between DHFR312T and higher
P. jirovecii burdens, also found in the present study (p 0.01) [18].
A very low frequency of DHFR polymorphic sequences was
reported in the PcP patients from the USA, between 1985 and
1998 (2.7%) [23]. In the present study, the frequency of
DHFR312C in the US patients was 14.8%. The reason for this
increase is not obvious. It may eventually reﬂect the selective
pressure of trimethoprim-induced polymorphisms caused by
the increased widespread use of trimethoprim-
sulfamethoxazole in the USA after the mid-1990s, or it may
be linked to the association between DHFR312T and the higher
P. jirovecii burdens normally found in AIDS-related PcP patients.
Similar distribution patterns of DHFR312 were observed
between the pools from Mozambique, Spain and Cuba. In a
retrospective study from South Africa, DHFR312C was not
observed in a heterogeneous population of patients with pul-
monary disorders (2000–2003) [39]. In Mozambique, the high
levels of DHFR polymorphic sequences detected in the present
study may reﬂect the increased widespread empirical use of
trimethoprim-sulfamethoxazole in the late 2000s and the se-
lective pressure of trimethoprim-induced polymorphisms.
SOD
In the present study, the distribution pattern of the SOD
polymorphic sequences in the Portuguese population
(SOD110C 8.8%–46.4% and SOD215T 8.0%–38.6%, time-
period 2004–2012) was identical to a previous report on
P. jirovecii multilocus genotyping in pooled DNA samples [21].
The highest frequencies of SOD110C (46.4%) and SOD215T
(38.6%) were observed in the PT2 pool, supporting the hy-
pothesis that the genotype SOD110C/SOD215T is linked to
higher P. jirovecii burdens [18,21].
The US pool (AIDS-related PcP, most receiving mechanical
ventilation) showed the most distinct distribution pattern of the
SOD alleles (SOD110C 64.9%, SOD215T 50.6%). Again, the alleles
SOD110C and SOD215T were statistically associated with this
pool (Table 3), supporting also the relationship between the
genotype SOD110C/SOD215T and more virulent PcP episodes.
The distribution patterns of the SOD alleles were similar
among the pools from Mozambique (SOD110C 13.4%,
SOD215T 12.6%), Spain (SOD110C 14.6%, SOD215T 8.6%) and
Cuba (SOD110C 2.9%, SOD215T 2.4%). The pool fromLtd. All rights reserved, CMI, 22, 566.e9–566.e19
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previous study in Zimbabwean AIDS-related PcP patients, in
2004 (SOD110C 33.3%, SOD215T 33.3%) [28]. A possible
explanation of this difference is related to the distinct clinical
populations studied, reﬂecting the possible association between
more virulent PcP episodes, reported in Zimbabwe, and the
genotype SOD110C/SOD215T.
Low frequencies of SOD110C and SOD215T were observed
in the pools from Spain and Cuba. However, in a recent study
involving young Cuban children with whooping cough, colo-
nized by P. jirovecii, the frequencies of SOD110C and SOD215T
(time period 2010–2013) were much higher, 42.0% and 71%,
respectively [6]. The reason for this discrepancy is not obvious.
We hypothesize that this difference is due to distinct sample
sizes (190 respiratory specimens in the previous report and ten
in the present study) biasing the results, and/or to different
underlying concomitant pulmonary diseases, in both Cuban and
Spanish colonized populations. The low frequencies of
SOD110C and SOD215T alleles are usually associated with more
virulent PcP episodes.
The relationships between the most frequent P. jirovecii pu-
tative MLG detected in the different pools studied pointed out
that clusters are mainly due to the geographic differences but
also dependent on clinical characteristics of the populations
studied (Fig. 2). MLG from pools corresponding to colonized
patients from Portugal and Spain were grouped in the same
cluster (cluster A). Also, the MLG from the pool from Cuba
(infants infected with P. jirovecii) was included in this cluster but
with a higher phylogenetic distance. The majority of the MLG
detected in the Portuguese pools were clustered, corresponding
to PcP cases (cluster B). Pneumocystis jirovecii from the USA and
Mozambique were related in the same cluster because of the
DHPS mutations present in both MLG (cluster C). However,
within this cluster the MLG from Mozambique (infants infected
with P. jirovecii) was considerably distant from the four major
MLG detected in the pool from the USA (severe AIDS-related
PcP cases).
The observation of different dihydropteroate synthase
(DHPS) alleles in and between P. jirovecii populations carries
epidemiological implications related to transmission patterns,
sulfa drug exposure and geographical distribution of speciﬁc
genotypes [14,15,17]. In general overview, patients living in the
USA and Mozambique presented higher rates of DHPS mutants,
which is clearly depicted in Fig. 1. This fact suggests that the
circulation of P. jirovecii haplotypes may be potentially related to
trimethoprim-sulfamethoxazole resistance in those geograph-
ical regions. The high frequencies of DHFR312T and SOD110C/
SOD215T detected in patients with AIDS-related PcP from
Portugal and the USA endorse the importance of these genetic© 2016 European Society of Clinical Microbiology and Infvariants of P. jirovecii, which were already associated with the
virulence or severity of the disease (Table 3) [18,21]. Consid-
ering the present data, P. jirovecii with the haplotype DHFR312T/
SOD110C/SOD215T is likely to be associated with more severe
AIDS-related PcP cases and high P. jirovecii burdens as demon-
strated in the pools from patients with severe PcP from
Portugal (PT2) and the USA.ConclusionGeographic location and clinical parameters of the groups of
patients studied as well as the time-period in which the samples
are obtained, were conﬁrmed as determinant epidemiological
factors of P. jirovecii infection. The present study demonstrates
that the multifactorial approach to PcP studies is a powerful
high-throughput methodology for large-scale screening of
P. jirovecii SNP of epidemiological relevance. These results
convey a more complete picture of the worldwide distribution
of P. jirovecii haplotypes and assess their epidemiological impact
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